MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

09/03/2014 by Brad Perriello

David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.


Last year, when Harvard Bioscience (NSDQ:HBIO) spun out its regenerative medicine business as...

08/15/2014 by Arezu Sarvestani

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

07/31/2014 by Brian Johnson

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

The CardioMEMS story didn't end when St. Jude Medical (NYSE:STJ) acquired the Georgia-based company in June, paying $375 million for the stake it didn’t already own, valuing the implantable heart failure monitor company at $463 million total.

But the deal did end an 11-year commitment by...

07/10/2014 by Brad Perriello

Calhoun Vision CEO Verne Sharma tells why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

For years the Holy Grail of ophthalmology has been to give patients the ability to see clearly both and near and far distances. Verne Sharma, CEO of Calhoun Vision, thnks his company's light-adjustable lens has reached that goal.

The LAL device uses a unique blend of light-sensitive polymers to...

07/07/2014 by Arezu Sarvestani

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

Digital health is all the rage in Silicon Valley, especially as consumer technology's biggest players are getting more interested in tracking health and fitness. But for companies like iRhythm,...

06/02/2014 by Brad Perriello

Transcend Medical CEO Brian Walsh tells why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma.

Brian Walsh looks to transcend glaucoma treatment with micro-stent

Until recently, the treatment for glaucoma – a group of diseases that cause pressure within the eyeball – consisted of several options, none of them ideal. Patients could opt for medicines, either oral or via eyedrops, to lower eye pressure. A surgical option that in essence creates a drain in the eyeball...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp